Silver Creek Pharmaceuticals Appoints Dr. Ross Breckenridge to Board of Directors

SAN FRANCISCO, Sept. 16, 2015 /PRNewswire/ -- Silver Creek Pharmaceuticals, Inc. today announced that Dr. Ross Breckenridge, a recognized leader in cardiovascular medicine, was appointed to its Board of Directors. Dr. Breckenridge serves as senior clinical lecturer and Program Director for the Masters Program in Clinical and Experimental Medicine at the University College London, and practicing physician at University of College London Hospital. Dr. Breckenridge currently serves on the boards of Reva Medical Inc., Senrigan Capital, Empower India, and the Cornelia de Lange Society of Great Britain; he provides consultation services to investors in the biotech and healthcare sector.

"Dr. Breckenridge has deep expertise in cardiovascular science, medicine and biotechnology; he will bring critical strategic and practical insight to Silver Creek," said Silver Creek's CEO, Matt Onsum. "I am pleased to welcome Ross to our Board." 

"I look forward to helping Matt and the Silver Creek team build a company that will create medicines for patients whose needs are not met by current approaches," said Dr. Breckenridge.

Dr. Breckenridge obtained his medical degree from Oxford University, and a PhD in Developmental Biology at the University of Cambridge. He completed his training in Clinical Pharmacology at University College London, and is now on the faculty. He focuses on the heart's response to low levels of oxygen, and identifying novel therapeutic targets for heart disease.

About Silver Creek Pharmaceuticals
Silver Creek is pioneering a new class of medicines (Smart Growth Factors^TM) to repair and regenerate functional tissues. These molecules are designed to promote resilience and regeneration of damaged tissues after acute or chronic injury.  Growth factor therapies have been hindered by short half-lives and off-target effects. Silver Creek's technology improves their efficacy by using computational design and systems modeling to engineer therapeutics that improve tissue specificity and prolong activation. Preclinical research demonstrates that this enables the Company's SGFs to potently act at the site of damage with minimal impact on healthy cells. Silver Creek was carved out from Merrimack Pharmaceuticals, Inc. in 2010, and focuses on treatments for heart and kidney disease.

SOURCE Silver Creek Pharmaceuticals, Inc.

Related Links

http://www.silvercreekpharma.com